Brilacidin clinical trials
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2010
How each study uses brilacidin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2010 (1)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2014 | 1 |
| 2020 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Innovation Pharmaceuticals, Inc. (2) · Cellceutix Corporation (1) · PolyMedix, Inc. (1)
Studies
Open first, then newest update. How each study uses brilacidin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19CompletedPhase 2Innovation Pharmaceuticals, Inc.NCT04784897Written as Brilacidin
- A Study to Investigate the Use of Delayed Release Tablets for Colonic Delivery of Brilacidin in Healthy VolunteersCompletedPhase 1Innovation Pharmaceuticals, Inc.NCT04240223Written as Brilacidin
- Efficacy and Safety Study of Brilacidin to Treat Serious Skin InfectionsCompletedPhase 2Cellceutix CorporationNCT02052388Written as Brilacidin
- Initial Treatment for Acute Bacterial Skin Infections (ABSSSI) Caused by Staphylococcus AureusCompletedPhase 2PolyMedix, Inc.NCT01211470Written as PMX-30063-investigational drug
As the comparator · 1 — what is tested is compared with brilacidin
Codes
What other systems call brilacidin · ClinicalTrials.gg INT000546
- MeSH (NLM) C000611530brilacidinConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) I1679X069HBRILACIDINConfirmed FDA, NLM, Wikidata
- Wikidata Q15408420brilacidinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C169816BrilacidinOne source FDA
- DrugBank DB12997One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000611530 | brilacidin | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | I1679X069H | BRILACIDIN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q15408420 | brilacidin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C169816 | Brilacidin | One source FDA |
| DrugBank | DB12997 | — | One source Wikidata |
Also registered as brilacidin tetrahydrochloride (UNII CM3HYX69SK).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.